The Future of Melanoma: What to Anticipate in 2023 with Neoadjuvant and Adjuvant Pembrolizumab

This one-hour presentation is offered virtually for melanoma patients, family members, and loved ones. The Future of Melanoma: What to Anticipate in 2023 Moderated by Samantha Guild, President, AIM at Melanoma With Janice Mehnert, MD and Erica B. Friedman, MD, from NYU Langone’s Perlmutter Cancer Center. Drs. Mehnert and Friedman will discuss the following: – S1801: Neoadjuvant and Adjuvant Pembrolizumab for Patients With Stage IIIB to IV Melanoma – Phase 3 DREAMseq trial – Margins in melanoma – Management of patients with positive sentinel lymph nodes NYU Langone Health is one of the nation’s premier academic medical centers. Their trifold mission to serve, teach, and discover is achieved daily through an integrated academic culture devoted to excellence in patient care, education, and research.